Overview Financials News + Filings Key Docs Charts Holdings Ownership Insiders
|
|
AVEO PHARMACEUTICALS, INC. (AVEO)
|
Add to portfolio |
|
|
|
| Price: |
$5.27
| | Metrics |
| OS: |
34.8
|
M
| |
-101
|
% ROE
|
| Market cap: |
$183
|
M
| |
|
|
|
Net cash:
|
$38.7
|
M
| |
$1.11
|
per share
|
|
EV:
|
$144
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($24.4)
|
M
| |
|
|
|
EBIT
|
($24.5)
|
M
| |
|
|
| EPS |
($0.84)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 42.3 | 6.0 | 28.8 | 5.4 | 7.6 | 2.5 | 19.0 | 18.1 |
| Revenue growth | 602.7% | -79.1% | 432.4% | -28.6% | 201.4% | -86.8% | 5.0% | 1301.6% |
| Cost of goods sold | 4.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 37.6 | 6.0 | 28.8 | 5.4 | 7.6 | 2.5 | 19.0 | 18.1 |
| Gross margin | 88.8% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Selling, general and administrative | 60.8 | 22.2 | 11.2 | 10.8 | | | | |
| Research and development | 26.3 | 22.7 | 18.0 | 20.7 | 25.2 | 23.7 | 12.9 | 38.3 |
| General and administrative | | | | | 9.1 | 8.2 | 10.2 | 18.6 |
| EBIT | -49.8 | -43.8 | -12.0 | -26.0 | -28.8 | -29.4 | -8.1 | -38.7 |
| EBIT margin | -117.6% | -727.3% | -41.5% | -481.1% | -380.1% | -1168.7% | -42.4% | -213.7% |
| Pre-tax income | -53.3 | -35.6 | 9.4 | -5.3 | -64.9 | -26.8 | -15.0 | -52.7 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | | | 0.0% | 0.0% |
| Net income | -53.3 | -35.6 | 9.4 | -5.3 | -65.0 | -26.9 | -15.0 | -52.7 |
| Net margin | -126.1% | -591.2% | 32.6% | -98.5% | -858.0% | -1069.1% | -78.9% | -291.0% |
| |
| Diluted EPS | ($1.63) | ($1.66) | $0.20 | ($0.41) | ($6.14) | ($0.39) | ($0.27) | ($1.01) |
| Shares outstanding (diluted) | 32.7 | 21.4 | 46.1 | 13.1 | 10.6 | 69.3 | 55.7 | 52.3 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|